Acute Coronary Syndromes and SARS-CoV-2 Infection: Results From an Observational Multicenter Registry During the Second Pandemic Spread in Lombardy

Background COVID-19 had an adverse impact on the management and outcome of acute coronary syndromes (ACS), but most available data refer to March-April 2020. Aim This study aims to investigate the clinical characteristics, time of treatment, and clinical outcome of patients at hospitals serving as macro-hubs during the second pandemic wave of SARS-CoV-2 (November 2020-January 2021). Methods and Results Nine out of thirteen “macro-hubs” agreed to participate in the registry with a total of 941 patients included. The median age was 67 years (IQR 58-77) and ST-elevation myocardial infarction (STEMI) was the clinical presentation in 54% of cases. Almost all patients (97%) underwent coronary angiography, with more than 60% of patients transported to a macro-hub by the Emergency Medical Service (EMS). In the whole population of STEMI patients, the median time from symptom onset to First Medical Contact (FMC) was 64 min (IQR 30-180). The median time from FMC to CathLab was 69 min (IQR 39-105). A total of 59 patients (6.3%) presented a concomitant confirmed SARS-CoV-2 infection, and pneumonia was present in 42.4% of these cases. No significant differences were found between STEMI patients with and without SARS-CoV-2 infection in treatment time intervals. Patients with concomitant SARS-CoV-2 infection had a significantly higher in-hospital mortality compared to those without (16.9% vs. 3.6%, P < 0.0001). However, post-discharge mortality was similar to 6-month mortality (4.2% vs. 4.1%, P = 0.98). In the multivariate analysis, SARS-CoV-2 infection did not show an independent association with in-hospital mortality, whereas pneumonia had higher mortality (OR 5.65, P = 0.05). Conclusion During the second wave of SARS-CoV-2 infection, almost all patients with ACS received coronary angiography for STEMI with an acceptable time delay. Patients with concomitant infection presented a lower in-hospital survival with no difference in post-discharge mortality; infection by itself was not an independent predictor of mortality but pneumonia was.

[1]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[2]  C. Cuccia,et al.  Acute coronary syndromes during the first and the second wave of COVID-19 , 2022, European Journal of Internal Medicine.

[3]  G. Hindricks,et al.  ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up , 2021, Cardiovascular research.

[4]  G. Hindricks,et al.  ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up , 2021, European heart journal.

[5]  B. Gersh,et al.  International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19 , 2021, Journal of the American College of Cardiology.

[6]  Brian C. Case,et al.  Initial Findings From the North American COVID-19 Myocardial Infarction Registry , 2021, Journal of the American College of Cardiology.

[7]  D. Kazi,et al.  Cardiovascular Deaths During the COVID-19 Pandemic in the United States , 2021, Journal of the American College of Cardiology.

[8]  F. D’Ascenzi,et al.  COVID-19 and Acute Coronary Syndromes: Current Data and Future Implications , 2021, Frontiers in Cardiovascular Medicine.

[9]  Massimo Siviglia,et al.  Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI , 2020, Journal of the American College of Cardiology.

[10]  M. Metra,et al.  Management of acute coronary syndromes during the COVID-19 outbreak in Lombardy: The “macro-hub” experience , 2020, IJC Heart & Vasculature.

[11]  A. Bozorgi,et al.  The impact of a dedicated coronavirus disease 2019 primary angioplasty protocol on time components related to ST-segment elevation myocardial infarction management in a 24/7 primary percutaneous coronary intervention-capable hospital. , 2020, Kardiologia polska.

[12]  R. Petraco,et al.  Optimal management of acute coronary syndromes in the era of COVID-19 , 2020, Heart.

[13]  G. Musumeci,et al.  Catheterization laboratory activity before and during COVID-19 spread: A comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE) , 2020, International Journal of Cardiology.

[14]  J. Zamorano,et al.  Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak , 2020, Revista Española de Cardiología (English Edition).

[15]  G. Esposito,et al.  Epidemiology, prognosis, and clinical manifestation of cardiovascular disease in COVID-19 , 2020, Expert review of cardiovascular therapy.

[16]  R. de Caterina,et al.  Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era , 2020, European heart journal.

[17]  Susanna Price,et al.  EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic , 2020, European heart journal.

[18]  Catherine Klersy,et al.  Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy , 2020, The New England journal of medicine.

[19]  M. Metra,et al.  Centralization of the ST elevation myocardial infarction care network in the Lombardy region during the COVID-19 outbreak , 2020, International Journal of Cardiology.

[20]  C. Siu,et al.  Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China , 2020, Circulation. Cardiovascular quality and outcomes.

[21]  Marco Valgimigli,et al.  [2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.] , 2018, Kardiologia polska.

[22]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[23]  A. Khwaja KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[24]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[25]  K. Eagle,et al.  Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.